Charles A. Deignan
2021
In 2021, Charles A. Deignan earned a total compensation of $1.5M as Chief Financial Officer at Clearside Biomedical, a 141% increase compared to previous year.
Compensation breakdown
| Bonus | $14,000 |
|---|---|
| Non-Equity Incentive Plan | $134,048 |
| Option Awards | $647,601 |
| Salary | $353,163 |
| Stock Awards | $386,404 |
| Other | $9,600 |
| Total | $1,544,816 |
Deignan received $647.6K in option awards, accounting for 42% of the total pay in 2021.
Deignan also received $14K in bonus, $134K in non-equity incentive plan, $353.2K in salary, $386.4K in stock awards and $9.6K in other compensation.
Rankings
In 2021, Charles A. Deignan's compensation ranked 7,134th out of 12,415 executives tracked by ExecPay. In other words, Deignan earned more than 42.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,134 out of 12,415 | 43rd |
Division Manufacturing | 3,120 out of 5,505 | 43rd |
Major group Chemicals And Allied Products | 1,377 out of 2,375 | 42nd |
Industry group Drugs | 1,226 out of 2,096 | 42nd |
Industry Pharmaceutical Preparations | 897 out of 1,546 | 42nd |
Source: SEC filing on April 29, 2022.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2021.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019